Krystal Biotech, based in Pittsburgh, focuses on developing genetic medicines for diseases with high unmet needs, employing 229 staff since its IPO in September 2017. Its products include VYJUVEK for DEB and others targeting cystic fibrosis and solid tumors.
KRYS has been in the news recently: On June 30, several key individuals at Krystal Biotech (KRYS), including Director Julian S. Gangolli and Board Members Everett Rand Sutherland and Mason, reported significant stock option transactions in SEC filings. Additionally, Janney and Dino A. Rossi, also associated with the company, exercised or acquired stock options on the same date.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
